Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops candidate products targeting neurological diseases and rare disorders in the United States. The company is headquartered in New Haven, Connecticut. Show more

215 CHURCH STREET, NEW HAVEN, CT, UNITED STATES, 06510, New Haven, CT, 06510, USA

BIOTECHNOLOGY
HEALTHCARE

Market Cap

1.932B

52 Wk Range

$7.48 - $18.57

Previous Close

$15.00

Open

$13.52

Volume

8,322,113

Day Range

$12.44 - $13.84

Enterprise Value

2.253B

Cash

238M

Avg Qtr Burn

-85.1M

Insider Ownership

11.21%

Institutional Own.

96.66%

Qtr Updated

06/30/26


Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 3

Data readout

Troriluzole (BHV-4157) Details
Obsessive compulsive disorder

Phase 3

Update

VYGLXIA (troriluzole) Details
Spinocerebellar Ataxia

Phase 3

Update

BHV-1300 Details
Rheumatoid arthritis, Autoimmune disease, Graves’ disease

Phase 3

Update

BHV-1400 Details
IgA nephropathy

Phase 3

Initiation

BHV-7000 Details
Bipolar disease

Phase 2/3

Data readout

BHV-8000 Details
Parkinson's Disease

Phase 2/3

Data readout

BHV-7000 Details
Focal Epilepsy

Phase 2/3

Data readout

Phase 2

Data readout

BHV-7000 Details
Major depressive disorder

Phase 2

Update

Opakalim (BHV-7000) (Kv7 Activator) Details
Idiopathic Generalized Epilepsy

Phase 2

Update

Phase 2

Update

BHV-1510 Details
Epithelial Tumors

Phase 1/2

Update

BHV-1600 Details
Cardiomyopathy

Phase 1

Data readout

BHV-1530 Details
Urothelial cancers

Phase 1

Data readout

Opakalim (BHV-7000) (Kv7 Activator) Details
KCNQ2 Developmental And Epileptic Encephalopathy

Phase 1

Update

Phase 1

Update

Phase 1

Update

BHV-1310 Details
IgG4-related disease

Phase 1

Initiation